{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'DMT Phase', 'Alemtuzumab treatment phase', 'Unscheduled', 'visits', 'Visita', 'Scrn.', 'Period 1/ Prior DMT', 'MO/', 'M1', 'M2', 'M3', 'M4', 'Period 2', 'M9', 'M10', 'M11', 'M12', 'Relapse visit', 'visit6', 'phase', 'D1U', 'Eligibility', 'D-14 to', 'M5', 'M6', 'M7', 'M8', 'confirmation', 'D-7C', 'on M-4', 'Visit number', 'V1', 'V2', 'V3', 'V4v', 'V5', 'V6', 'V7', 'V8', 'V9', 'V10', 'V11', 'V12', 'V13', 'V14', 'V15', 'V16v', 'Efficacy:', 'EDSS', 'X', 'Brain MRI', 'SDMT', 'X', 'BVMT-R test', 'X', 'PedsQL (QoL Questionnaire)/Ped. Neuro-QoL', 'X', '(sub-comp.)', 'Safety:', 'Physical examination', 'X', 'Clinical chemistry laboratories', 'X', 'Hematology (Differential CBC)\u00b0', 'X', 'Thyroid Function Testso', 'Urinalysis9', 'Serum Creatinine and alanine aminotransferase', 'Lymphocyte phenotyping', 'Samples for antibodies to Study Drug', 'Tanner Staging', 'AE/SAE recording (if any)', 'Vital Signs', 'X', 'Laboratory testing:', 'Pregnancy test (for female patients of', 'childbearing potential\u00b2', 'PK sampling', 'xu', 'xu', 'Immune Marker Sampling (optional)', 'Abbreviations: AE: adverse event; BVMT-R: brief visuospatial memory test-revised, CBC: complete blood count; D: day; DMT: disease modifying therapy; EDSS: Expanded Disability Status Scale; M month(s);', 'MRI: magnetic resonance imaging; Neuro-QoL: quality of life in neurological disorders; Ped: paediatric; PK: pharmacokinetics; QoL: quality of life; SAE: serious adverse event; Scrn: screening; SDMT: symbol digit', 'modality test', 'a Recommended windows: The window for obtaining samples and performing assessments at any given visit will be +7 days, except for the D-14 to D-7 day visit which should occur between -7 to -1 days prior to', 'MO/D1and for Visit 16 (M12) which can occur within -7 days or +30 days of the scheduled visit. All post M0/D1 treatment period assessments should be completed within +7 days of the scheduled visit date relative', 'to the M0/D1 visit.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0254406: 5.0', 'Page 15']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'b Screening visit should be a maximum of 28 days prior to eligibility confirmation (M-4). If needed, the assessments can be performed over multiple days as long as the window is observed.', 'C Some premedications should have been taken prior to Day 1. All lab results/assessments should be available prior to D-7 to confirm patient eligibility. If patient is eligible to receive alemtuzumab a follow-up call', 'should be performed and INF/copaxone should be stopped at D-7.', 'd', 'This visit is only required for subjects who have a suspected relapse, and should occur within 7 days following the occurrence of the clinical event.', 'e Subject race will be collected in this study because these data are required by several regulatory authorities.', 'f Information on alcohol habits will be collected along with medical history at Visit 1 and in case of alanine aminotransferase (ALT) increase.', 'g Phone calls to remind patients and parents about continuation of DMT and participation in study will be utilized at monthly intervals (between V2 and V3) in prior DMT period (Period 1). The phone calls will be', 'captured in the e-CRF.', 'h Screening tuberculosis test should be performed as per local health care authority recommendations and during the study if deemed clinically indicated. Blood testing (QuantiFERON\u00ae-TB Gold test) or skin testing', 'on site (purified protein derivative [PPD] skin test) willbe allowed only if the Quantiferon TB Gold test is used. Blood testingis preferred where available. If Quantiferon test results are indeterminate, confirmation', 'via skin testing is required.', 'i', 'Serological testing for Herpes zoster is recommended, in accordance with local public health authority recommendations. Herpes zoster (varicella zoster) vaccination (VZV) of antibody-negative patients should be', 'considered prior to treatment with alemtuzumab. In addition if patient receives any vaccination during screening or Alemtuzumab Treatment Phase, relevant antibody titers will be assessed before and', 'approximately 6 weeks after completing vaccination course (inactivated vaccines only).', 'j', 'Testing will be conducted for human papillomavirus (HPV) infection as and when recommended by local public health authorities. If the testing is positive, the patient may be eligible after the condition has resolved', 'as per the Investigator opinion (eg, follow-up HPV test is negative or cervical abnormality has been effectively treated). An annual follow-up is recommended.', 'k Acyclovir 200 mg twice daily (or a therapeutic equivalent) starting on the first day of each alemtuzumab course and continuing for a minimum of 1 month following treatment with alemtuzumab.', '/ The MRI assessment will be 4 months (7 days) apart in Year 1. The MRI assessments will be available to investigators to assess safety.', 'm PedsQL questionnaire (Paediatric Quality of Life Inventory) will be completed by patients/parents based on recommendations. Peds NeuroQoL is a quality of life measurement developed for neurological disorders', 'and consists of short form questions for multiple domains. Specific subdomains will be utilized.', \"n The date of first menarche should be captured if applicable. 'A standard physical examination for clinical and neurological assessments includes examination of major body systems, height and body weight.\", 'o', 'Hematology and differential panel (hemoglobin, hematocrit, red blood cell count, mean corpuscular hemoglobin, white blood cell count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets)', 'Complete chemistry panel (glucose, creatinine, blood urea nitrogen (BUN), sodium, potassium, chloride, bicarbonate, magnesium, calcium uric acid, aspartate aminotransferase (AST), ALT, gamma-glutamyl', 'transpeptidase (GGT), lactate dehydrogenase (LDH), total bilirubin, direct/indirect bilirubin, alkaline phosphatase, inorganic phosphorus, total protein, albumin, globulin, albumin/globulin ratio, triglycerides,', 'cholesterol and creatine phosphokinase (CPK). It is preferred that CBCs with platelet count, and monitoring for any cytopenia as well as serum creatinine, and urinalysis with microscopy be analyzed at the central', 'laboratory, but under special circumstances (eg, if patient is unable to visit the study center weekly or monthly, or results are needed urgently), the assay may be performed at a local laboratory provided that test', 'results are entered into the e-CRF in a timely manner. However for study visits that only require laboratory sampling, home nursing or local laboratories may be used for sample collection and shipment to the', 'central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs.', 'p', 'Thyroid stimulating hormone (TSH) & if abnormal T3 & T4 performed on the existing samples. However for study visits that only require laboratory sampling, home nursing or local laboratories may be used for', 'sample collection and shipment to the central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and concomitant medications.', 'q Urinalysis (pH, ketones, cells, protein, glucose, blood, urobilinogen, bilirubin, microscopic sediment, specific gravity). However for study visits that only require laboratory sampling, home nursing or local', 'laboratories may be used for sample collection and shipment to the central laboratory, as per local regulations. These visits are to be followed by telephone calls from the study site to assess AEs and concomitant', 'medications.', 'r', 'Tanner stage to be assessed as noted until complete sexual maturity.', 'S', 'The following vital signs will be recorded before methylprednisolone infusion, at a time after methylprednisolone infusion and prior to alemtuzumab infusion; and 1 hour after the start of alemtuzumab infusion and', 'hourly during and after infusion, until 2 hours after infusion has ended or longer until stabilization: systolic and diastolic blood pressure (millimeters of mercury [mm Hg]), heart rate (beats/minute), respiratory rate', '(breaths/minute), and temperature (degrees Celsius [\u00b0C] or degrees Fahrenheit [\u00b0F]).', 't', '\u00df-human chorionic gonadotropin test will be performed at Screening. Pregnancy test after Screening will be done by urine dipstick and must be conducted prior to methylprednisolone administration; pregnancy', 'testing is required for all female patients capable of bearing children and who have commenced menstruating. Those female patients who commence initial menstruation during the study will be similarly monitored', 'with urine dipstick pregnancy tests for the duration of the study. Pregnancy testing to be repeated as permitted by national law.', 'u', 'For details on PK sampling, refer Section 1.2.4.', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0254406 5.0', 'Page 16']\n\n###\n\n", "completion": "END"}